Formycon AG and its License Partner Klinge Biopharma GmbH Report the BLA Submission of FYB203 (biosimilar, aflibercept) to the US FDA
Shots:
- Formycon AG and its license partner Klinge Biopharma GmbH submit BLA for FYB203, a biosimilar candidate for Eylea
- Eylea is indicated for the treatment of nAMD and other severe retinal diseases & inhibits vascular endothelial growth factor for the excessive formation of blood vessels in the retina
- Additionally, six biosimilars are currently being developed by Formycon. The company is also working on the development of FYB207, based on its extensive experience in the development of biopharmaceutical drugs
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon AG Reports Preliminary P-III Trial (MAGELLAN-AMD) Results FYB203, a Proposed Biosimilar to Eylea
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
